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Abstract
Until recently, our understanding of the cellular tropism of human norovirus (HuNoV), a major cause of viral gastroenteritis,
has been limited. Immune cells and intestinal epithelial cells (IECs) have been proposed as targets of HuNoV replication in
vivo, although the contribution of each to pathogenesis and transmission is unknown. Murine norovirus (MNV) is widely used
as a surrogate model for HuNoV, as it replicates in cultured immune cells. The importance of the complete MNV immune cell
tropism in vivo has not been determined. Recent work has linked replication in IECs to viral persistence in vivo. MNV provides
a model to assess the relative contribution of each cell tropism to viral replication in immunocompetent native hosts. Here
we exploited cell-specific microRNAs to control MNV replication, through insertion of microRNA target sequences into the
MNV genome. We demonstrated the utility of this approach for MNV in vitro by selectively reducing replication in microglial
cells, using microglial-specific miR-467c. We then showed that inserting a target sequence for the haematopoietic-specific
miR-142-3p abrogated replication in a macrophage cell line. The presence of a target sequence for either miR-142-3p or IEC
miR-215 significantly reduced viral secretion during the early stages of a persistent infection in immunocompetent mice,
confirming that both cell types support viral replication in vivo. This study provides additional evidence that MNV shares the
IEC tropism of HuNoVs in vivo, and now provides a model to dissect the contribution of replication in each cell type to viral
pathogenesis and transmission in a native host.
INTRODUCTION
Human noroviruses (HuNoVs) are a major cause of viral
gastroenteritis worldwide, across all age groups [1], and
cause between 2–6million infections each year in the UK
alone [2]. HuNoVs represent a particular problem in
healthcare settings, with 4000 hospital outbreaks reported in
a 2-year period in the UK, resulting in over 9000 ward clo-
sures and a significant economic cost to the National Health
Service [3]. Whilst most infections are acute, chronic infec-
tions in immunocompromised individuals are a significant
cause of morbidity and mortality [4]. In low- and middle-
income countries (LMICs), HuNoVs account for over
200 000 deaths in children under 5 each year [5], although a
full picture of the impact and prevalence in LMICs has only
recently begun to emerge [6, 7].
Despite the global burden, there are still no licensed antivi-
rals or a vaccine. Although HuNoV was identified in 1972
[8], robust in vitro propagation systems have only been
developed in the past 3 years [9, 10]. A major hurdle in the
development of a permissive cell culture system was that,
until recently, the cellular tropism of HuNoVs in vivo
remained unclear. Both immune cells and epithelial cells
have been implicated as the primary cellular targets for
HuNoVs [9–11]. Evidence of HuNoV antigens in immune
cells has been provided by numerous animal infection mod-
els, including chimpanzees, piglets and immunocompro-
mised mice [12–14]. These studies led to the first
demonstration of HuNoV replication in vitro, in a cultured
B cell line (BJAB) [10]. Replication in BJAB cells is modest
and requires the presence of enteric bacteria expressing
histo-blood group antigens (HBGAs) or soluble HBGAs,
which serve as attachment factors for HuNoVs to facilitate
entry. Intestinal epithelial cells (IECs) are targeted by a vari-
ety of enteric pathogens that cause gastroenteritis, and as
such have also been considered to be candidate target cells
for HuNoVs. However, many studies have tried and failed
to find epithelial cell lines that are permissive for infection
[15–17]. Evidence of HuNoV replication in IECs in vivo
came from studies of symptomatic HuNoV infection in
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gnotobiotic pigs, where viral non-structural proteins,
markers of active replication, were observed in enterocytes,
the most abundant type of IEC [18]. A recent seminal study
using intestinal biopsies from chronically infected patients
revealed the presence of non-structural proteins and geno-
mic replication intermediates in IECs, suggesting that they
are a target cell type for HuNoV in vivo [11], at least in
immunocompromised individuals. This study paved the
way for the development of a robust in vitro replication sys-
tem using stem cell-derived enteroids, multicellular mono-
layers that recapitulate the natural intestinal epithelium [9].
This system supports the replication of diverse HuNoV
strains in enterocytes, present in the enteroids, and allows
the dissection of virus–host interactions [9]. The relative
contribution of HuNoV replication in enterocytes versus B
cells in vivo and how this links to pathogenesis and
transmission in immunocompetent hosts has not yet been
established. Likewise, the possibility that specialised tissue-
resident immune cell subsets may also serve as target cells
in vivo cannot be fully excluded [11].
Prior to the development and use of the B cell and enteroid
propagation systems for HuNoV, understanding of norovi-
rus replication has mainly come from studies using murine
norovirus (MNV) as a surrogate model, due to the availabil-
ity of efficient cell culture and reverse-genetics systems [19–
22]. Like HuNoV, MNV is enteric, spread predominantly
via the faecal–oral route and can cause both acute and per-
sistent infections in the natural host, depending on the
strain [23]. MNV replicates in macrophage, dendritic, B and
T cells in vitro [10, 19, 22]. Genomic replication intermedi-
ates were recently identified predominantly in these cell
types in the gut-associated lymphoid tissue of immunocom-
petent mice infected with an acute strain of MNV [22]. Rep-
lication in dendritic and B cells is important for acute and
persistent MNV infections in vivo, respectively [22, 24],
although the importance of the immune cell tropism as a
whole has not been determined.
Specialized microfold (M-cell) IECs have also been shown
to be important for MNV replication in vivo through the
transcytosis of viral particles across the intestinal epithelium
without active replication [25, 26]. Likewise, cultured IEC
cell lines do not support MNV replication in vitro [10].
However recent work, published during this study, has
established a correlation between the ability to replicate in
IEC, sensitivity to interferon lambda and viral persistence
in vivo [27]. Given its use a surrogate model, particularly for
dissecting host–pathogen interactions, it is important to
determine whether MNV shares the cellular tropism of
HuNoV. MNV also provides the opportunity to evaluate the
contribution of different cell types to norovirus replication
in vivo in a native immunocompetent host.
To further probe the role of both immune cells and IECs in
viral persistence we sought to explore use of the cellular
microRNA (miRNA) machinery to control MNV tropism.
This approach exploits the cell-specific nature and regula-
tory power of host miRNAs and has recently been used to
investigate the tropism of a number of RNA viruses. miR-
NAs are short non-coding RNAs (18–22nt) that post-
transcriptionally regulate gene expression by binding to
complementary sequences known as miRNA response ele-
ments (MREs) present in the open reading frame (ORF) or
3¢ UTR of messenger RNAs (mRNAs). The binding of a
miRNA targets an RNA-induced silencing complex (RISC)
onto the mRNA, which results in either translational silenc-
ing or mRNA cleavage, depending on whether the miRNA
has partial or perfect homology, respectively. Engineering
cell-specific MREs into a viral genome has been demon-
strated to regulate replication in a cell-specific manner, as
viral replication is targeted by the RISC complex in cells
expressing the cognate miRNA [28–33]. This approach has
been successfully used for poliovirus, Japanese encephalitis
virus, measles virus, influenza virus and dengue virus to
rationally generate live attenuated vaccine candidates,
enhance existing vaccine safety and improve the safety of
oncolytic viruses by preventing replication in non-tumour
cell lineages and tissues where it would lead to pathogenesis
[28–37]. Here, we first explored whether this approach
could be applied to MNV in vitro. We then exploited hae-
matopoetic- and IEC-specific miRNAs to probe the impor-
tance of each cell tropism to MNV replication during
persistent infection of an immunocompetent host. The pres-
ence of a MRE for either haematopoetic miR-142–3p or IEC
miR-215, but not scrambled control sequences, significantly
reduced replication in vivo, suggesting that both cell types
represent cellular targets for MNV during the early stages of
persistent infection in vivo.
RESULTS
Insertion of miR-467c target sequences into the
MNV genome restricts replication in microglial
cells and BMDM cells in vitro
To determine the potential of targeting the miRNA machin-
ery against MNV in vitro, as a proof of concept that this
approach can be applied to norovirus, we set out to specifi-
cally restrict replication in one of the two permissive cell
lines. We began by comparing miRNA expression in MNV-
1-infected murine macrophage RAW264.7 cells and murine
microglial BV-2s cells, with the aim of identifying a miRNA
that was expressed in only one of these cell lines. As many
microglial and macrophage miRNAs play a role in regulat-
ing the innate immune response [38–41], we analysed
miRNA expression at 20 h following MNV-1 infection at a
low multiplicity of infection (m.o.i.), to coincide with the
peak of interferon-stimulated gene induction in RAW264.7
cells, which we had identified previously [42]. Using Taq-
Man-based miRNA arrays, we compared the expression of
136 detectable miRNAs and identified 15 miRNAs that
were only expressed in BV-2 cells and 6 that were detected
solely in RAW264.7 cells (Fig. 1). We then validated three
of these from each cell line – miR-10a, miR-124 and miR-
125a-5p for RAW264.7 cells and miR-126–5p, miR-467a
and miR-467c for BV-2 cells – using RT-qPCR. Cell-specific
expression was validated for all of these miRNAs except
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miR-124, which was detected in both cell types (Table 1),
suggesting that amplification of this miRNA failed on the
arrays.
Of the validated miRNAs, we selected miR-467c to target
MNV replication, on the basis that it was one of the most
highly expressed BV-2-specific miRNAs. As the cellular
expression profile of miR-467c is not known, we also con-
firmed that it is expressed in bone marrow-derived macro-
phages (BMDMs), but importantly not in BSR-T7 cells,
which are used for viral recovery using our DNA-based
reverse-genetics system, Fig. 2(b).
To target miR-467c towards the MNV genomic RNA, it was
necessary to insert a cognate target sequence into the
genome without compromising replication. We have previ-
ously used transposon-mediated insertional mutagenesis to
identify positions across the norovirus genome that tolerate
the insertion of short nucleotide sequences without
compromising virus replication in cell culture [43]. Based
on this study, we inserted MREs for miR-467c into the
MNV-1 genome after nt 383 in the NS1-2 coding region of
ORF1 (Fig. 2a, c), which we have previously shown tolerates
Fig. 1. Comparison of miRNA expression profiles in MNV1-infected murine macrophage RAW264.7 cells and microglial BV-2 cells.
RAW264.7 and BV-2 cells were infected with MNV-1 at an m.o.i. of 0.1 TCID50/cell. The small RNA fraction was harvested at 20 h p.i.
Reverse transcription was performed using a set of primers for 380 miRNAs and control small RNAs, followed by qPCR analysis using
TLDA miRNA cards. The results for the 136 detectable miRNAs are shown. The Ct for each specific miRNA was normalized against the
Ct of the U6 control RNA to give the Delta Ct value shown on the y-axis. The higher the Delta Ct, the lower the expression. The boxed
points indicate miRNAs that are only expressed in one of the cell lines during MNV-1 infection, and the red boxes indicate miR-467c.
Table 1. Validation of the miRNA array data for a panel of
differentially expressed miRNAs
Array cell line miRNA RT-qPCR validation
RAW264.7 BV-2
miR-10a +  
RAW264.7 miR-124 + +
miR-125–5p +  
miR-126–5p   +
BV-2 miR-467a   +
miR-467c   +
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the insertion of a FLAG epitope tag coding sequence of the
same size as the MRE insertion (24 nt) [43, 44]. We intro-
duced a single MRE with either perfect or partial homology,
to direct different effector functions of RISC against the
genome. The partial homology was limited to three mis-
matches in order to to maintain the same amino acid
sequence as the perfect MRE sequence. The viruses were
designated as NS1-2-467cT or NS1-2-467cTM, where T
indicates target and M indicates a modified partial comple-
mentary target sequence (Fig. 2).
As expected, replication of NS1-2-467cT carrying a perfect
MRE was reduced by nearly 100-fold in BV-2 cells com-
pared to RAW264.7 cells, whereas wild-type (WT) MNV
replicated to the same level in both cell lines (Fig. 2c). Repli-
cation of the virus carrying the partially complementary tar-
get sequence (NS1-2-467cM) was also reduced in BV-2 cells
compared to RAW264.7 cells, indicating that the restriction
applies for both perfect and imperfect MREs. Replication of
NS1-2-467cT and NS1-2-467cTM was also significantly
reduced, by up to 100-fold, in BMDM cells (Fig. 2e), with
Fig. 2. Insertion of miR-467c target sequences into the MNV genome restricts replication in microglial cells and BMDMs. (a) miR-467c
target sequences were inserted into the coding region for NS1-2. (b) miR_467c is expressed in BV-2 and BMDM cells, but not
RAW264.7 and BSTR-T7 cells. ND, not detected, i.e. samples that fell below the limit of detection. (c) The miR-467c target sequence
was inserted to be complementary to miR-467c in the positive-sense gRNA (NS1-2-467cT) and with modified (M) sequence comple-
mentarity (NS1-2-467cM), but with the same coding sequence. (d) miR-467c T or M sequences specifically reduce replication in BV-2
cells expressing miR-467c. RAW267.4 and BV-2 cells were infected with each virus at a low m.o.i. (0.01 TCID50/cell) and titrated on
RAW264.7 cells, and virus was harvested at 24 h p.i. Significance was tested using two-way analysis of variance (ANOVA) with a
Dunnett post-test to compare the replication of each virus between the two cell lines. ***, P<0.001, n=3. (e) miR-467c target and modi-
fied target sequences reduce replication in BMDM cells. BMDMs were infected with each virus at an m.o.i. of 10 TCID50/cell and titrated
on RAW264.7 cells, and virus was harvested at 12 and 24 h p.i. Significance was tested using two-way ANOVA, with Sidak’s multiple
comparison test to compare the replication of each virus between the two cell lines. ***, P<0.001, n=3.
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the NS1-2-467cT virus displaying the largest defect at the
later time point.
Insertion of a MRE for haematopoetic-specific miR-
142–3p into the MNV genome inhibits replication in
macrophage cells in vitro
To use this approach to probe the importance of the
immune cell tropism in vivo we selected a miRNA with a
well-defined haematopoietic-specific expression profile. As
targeting the genome with miR-467c did not achieve com-
plete suppression in vitro (Fig. 2d, e) and its cellular expres-
sion is not well characterized, we employed one of the most
highly abundant haematopoetic-specific miRNAs, miR-
142–3p [45]. This miRNA has previously been used as a
tool to study dengue virus replication in haematopoietic
cells in a similar approach [33].
Examination of the array data (Fig. 1) and subsequent RT-
qPCR (Fig. 3c) confirmed that miR-142–3p is expressed in
both RAW264.7 and BV-2 cells, and at higher levels than
miR-467c in BV-2 cells. To assess the importance of tropism
during persistent infections in immunocompetent mice, we
inserted the MREs into the genome of the persistent MNV-
3 strain [21]. To avoid any impact of having the MRE in a
coding sequence, this time we inserted miR-142–3p MREs
into a site in the 3¢UTR, which we have previously identified
as being able to tolerate nucleotide insertions [43]. We
inserted one (3¢142T) or two (3¢142DT) perfectly comple-
mentary MREs into this site, alongside scrambled control
sequences of the same length and base composition (3¢S and
3¢DS), Fig. 3(b).
The presence of a single miR-142–3p MRE (3¢142T)
reduced replication to the limit of detection and a double
MRE (3¢142DT) completely prevented detectable viral repli-
cation in murine macrophage RAW264.7 cells (Fig. 3d). In
comparison, viruses carrying the single and double scram-
bled control sequences (3¢S and 3¢DS) replicated to the level
of WT MNV-3 (Fig. 3d). To determine that the loss of
observed replication was due to restriction in the
RAW264.7 target cells and was not a result of lower produc-
tion or stability of the RNA during virus recovery, we mea-
sured the level of the viral polymerase protein (NS7) and
intracellular genomes produced during virus rescue in BSR-
T7 cells. The NS7 and intracellular genomes levels were not
limiting for 3¢142T or 3¢142DT (Fig. 3e, f), which was indic-
ative of comparable transfection efficiency and no major
impact on RNA stability. To confirm that infectious virions
were produced for 3¢142T and 3¢142DT, we determined the
amount of nuclease-resistant encapsidated viral genomes
produced during virus recovery. The encapsidated genome
copies detected for the 3¢142T virus were comparable to
those for WT MNV-3 and 3¢S, although the double MRE
insertion resulted in a significant reduction for 3¢142DT,
and to a lesser extent for the double scrambled control
(Fig. 3g). As we could therefore not be sure that the loss of
3¢142DT replication in RAW264.7 cells was solely due to
miR-142–3p targeting and not an unknown effect on
genome encapsidation and viral assembly due to the size of
the insertion, we did not take the 3¢142DT virus forward for
further characterization. We made multiple attempts to
deplete miR-142–3p, using miRNA antagonists and
CRIPSR-Cas9 for miR-142–3p and Dicer, a key component
of the miRNA processing machinery, in order to further
confirm that miR-142–3p was responsible for the restriction
and to generate a cell line to be able to titre the targeted
viruses in the absence of miR-142–3p. However, due to the
macrophage cell lines being refractory to transfection and
the necessity of the miRNA machinery for regular cellular
function, it was not possible to obtain a reduction in miR-
142–3p levels using these approaches (data not shown).
We also compared the effect of inserting a single perfect
MRE for miR-467c into the same site in the 3¢UTR, along-
side a single scrambled control sequence of the same length
and base composition. The presence of the miR-467c MRE
reduced replication in BV-2 cells by nearly 10-fold in com-
parison to the scrambled control virus and WT-MNV-3,
but did not affect replication in RAW264.7 cells (Fig. 3h).
The differences in restriction resulting from each MRE at
the same site correlate with the expression level of the cog-
nate miRNA, where miR-142–3p is most highly expressed
and results in the greatest restriction.
MNV carrying a MRE for IEC-specific miR-215
replicates in macrophage cells
As IECs have recently been shown to be a target cell for
HuNoVs in vivo [11], to be able to confirm whether they
support MNV-3 replication in vivo, we next inserted a per-
fect MRE for the most abundant miRNA in murine IECs,
miR-215 [46] (Fig. 4a). miR-215 is not expressed in either
RAW264.7 or BV-2 cells (Fig. 2c) and there are no reports
of its expression in immune cells. Accordingly, the 3¢215T
virus recovered to levels that were comparable to those of
the WT and 3¢S control during reverse-genetics recovery
from BSR-T7 cells (Fig. 4b), and replication was not
restricted in RAW 264.7 cells (Fig. 4c). As MNV does not
replicate in cultured IEC lines [10], and as we could not
achieve sufficient transfection of either the macrophage or
microglial cell lines to exogenously express miR-215 (data
not shown), we were not able to further characterize the
restriction by miR-215 in vitro.
Carrying MREs for haematopoietic miR-142–3p and
IEC miR-215 reduces MNV-3 replication in the
initial phase of a persistent infection in vivo
To determine the effect of carrying a MRE for either miR-
142–3p or miR-215 on replication in vivo, we infected
immunocompetent mice with equal doses of MNV-3 WT,
3¢142T, 3¢215T and 3¢S, and monitored viral secretion.
Equivalent levels of viral genomes were secreted 1 day post-
infection (p.i.), which reflects equal inoculation doses and
shedding of the excess viral inoculum prior to the peak of
replication at 2 to 3 days p.i., as we have previously con-
firmed in this infection model [21]. At 2 days p.i. both the
3¢142T and 3¢215T viruses were secreted in the faeces at sig-
nificantly lower levels than the WT and 3¢S viruses, with a
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Fig. 3. Insertion of haematopoetic-specific miR-142–3p target sequences into the MNV genome inhibits replication in macrophage
cells. (a) miR-142–3p target sequences were inserted into a site in the MNV-3 3¢UTR that was previously found to tolerate nt insertions.
(b) Single and double perfectly complementary target sequences were inserted into the MNV-3 genomes, alongside single or double
scrambled control sequences. (c) miR-142–3p is expressed at higher levels than miR-467c in RAW264.7 and BV-2 cells. ND, not
Thorne et al., Journal of General Virology 2018;99:1621–1632
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more than 10-fold reduction in the average genome copies
mg 1 stool being observed (Fig. 5). There was no significant
difference in the level of the genomes secreted between the
3¢142T and 3¢215T viruses, suggesting that the replication
of both was equally restricted (Fig. 5). A significant defect in
the replication of these of these viruses was also observed at
3 days p.i., albeit to a lesser extent. The defect was fully
recovered by 5 days p.i.; both viruses established persistent
infections and were then secreted at comparable levels to
the WT and 3¢S for the duration of the experiment (Fig. 5).
To determine whether there were any mutations in the two
MREs, we sequenced the 3¢UTR of the secreted virus
population from each group of infected mice at 5 days p.i.
We observed no mutations in the WT or 3¢S 3¢UTR and
could not detect any changes in the 3¢142 or 3¢215 MREs
that would compromise binding of the cognate miRNAs
(data not shown).
DISCUSSION
Here we have exploited the cell-specific regulatory nature
of host miRNA expression to further define the cellular tro-
pism of MNV during persistent infection of immunocom-
petent hosts. Having demonstrated that this approach
could be applied to MNV in vitro, selectively targeting
detected, i.e. samples that fell below the limit of detection. (d) The insertion of single or double miR-142–3p target sequences reduces
replication in RAW264.7 cells. The recovery supernatants for each virus were titred on RAW264.7 cells to determine the TCID50 ml
 1.
The polymerase active site mutant (NS7 YGGG) was included as a replication-defective control. ND, not detected, i.e. samples that fell
below the limit of detection. (e) Production of the MNV-3 polymerase (NS7) or intracellular genomes (f) was not limiting during virus
recovery of 3¢142T or 3¢142DT, compared to the WT and scrambled controls. (g) Encapsidated genome copies, indicating infectious
virion production, were detected at WT-like levels for 3¢142T and 3¢S, but were significantly reduced for 3¢142DT and 3¢D. (h) Insertion
of a single microglial miR-467c target sequence into the 3¢UTR site selectively reduces replication in BV-2 cells. RAW264.7 nd BV-2
cells were infected with each virus at 0.01 TCID50 ml
 1 (titred on RAW264.7 cells) and virus was harvested at 24 h p.i. (d and g) Signifi-
cance was tested using one-way ANOVA with Dunnett’s post-test to compare replication of each virus to the WT. ****, P<0.0001;
*, P<0.05, n=3. LOD, limit of detection. (h) Significance was tested using two-way ANOVA, with Sidak’s multiple comparison test being
used to compare the replication of each virus between the two cell lines. *, P<0.05, n=3.
Fig. 4. MNV carrying a target sequences for intestinal epithelial cell-specific miR-215 replicates in macrophage cells. (a) A perfect tar-
get sequence for highly abundant IEC miR-215 was inserted into the 3¢UTR site in the MNV-3 genome alongside the scrambled control
sequence. (b) A virus carrying the miR-215 MRE (3¢215T) recovered to levels that were similar to those of the WT and scrambled con-
trol virus. (c) 3¢215T replicates with WT-like kinetics in RAW264.7 cells, which do not express miR-214. RAW264.7 cells were infected
with each virus at a low m.o.i. (0.01 TCID50/cell) and virus was harvested at 12 and 48 h p.i. LOD, limit of detection.
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replication in microglial cell lines, we then employed hae-
matopoietic-specific miR-142–3p and IEC miR-215 to
probe the importance of replication in these cell types in
vivo. The presence of a single target sequence for either
miRNA reduced viral secretion during the early phase of
infection in immunocompetent mice, which was indicative
of reduced replication. This provides additional evidence
that MNV actively replicates in IECs in vivo, and that in
addition to having an immune cell tropism, it also shares
the HuNoV tropism for IECs [11], at least during chronic
infections. MNV therefore now provides a surrogate model
to dissect and understand the contribution of each cell tro-
pism to pathogenesis and transmission, which remains
unknown for HuNoV infections.
During the preparation of this paper, evidence emerged that
supports our finding of MNV replication in IECs in vivo.
Lee et al. recently demonstrated that IECs serve as a reser-
voir for MNV during persistent infections in vivo [27].
Using a highly sensitive flow cytometry assay to detect two
non-structural proteins that are indicative of active viral
replication, they found that MNV maintains low-level infec-
tion of IECs during persistent infection, at a rate of approxi-
mately 20 infected cells per million IECs. These low infected
cell numbers, combined with the high background signals
they observed using single staining for viral proteins, sug-
gest why the infection of IECs has not been detected before
in similar studies [27]. They also show the utility of exploit-
ing the cellular miRNA machinery and the virus itself as a
tool to probe tropism as a complementary approach that
does not reply on staining protocols for viral detection.
Lee et al. demonstrated that the ability of MNV to infect
IECs correlated with an ability to persist in vivo, and was
determined by a combination of the action of MNV non-
structural (NS) protein NS1-2 and host cytokine interferon
lambda (IFNl) [27]. Studies from the same group
previously demonstrated that both of these factors can
determine the persistence of MNV in vivo [47–49], which
now neatly pinpoints IECs as the cell type in which inter-
play between MNV and components of host innate immune
response influences the outcome of persistent infections.
Clearance of MNV replication in IECs by IFNl treatment
correlated with a loss of viral secretion [27], suggesting that
replication in IECs results in the release of virus into the
intestinal lumen, and may therefore contribute to transmis-
sion, although this has yet to be demonstrated. It is striking
that the very low number of infected IECs may be solely
responsible for production of the high numbers of viruses
secreted during persistent MNV infection. This study did
not quantify the number of infected macrophage, dendritic
and B cells in the intestinal lamina propria, which would
provide an important comparison. This is especially rele-
vant as another recently published study identified immune
cells of the gut-associated lymphoid tissue as the predomi-
nant cell target during acute MNV infection in immuno-
competent hosts [22]. This study used RNAScope in situ
hybridization to detect both positive- and negative-sense
MNV genomic RNA, which were also observed at very low
frequency in the follicule-associated epithelium, and the
contribution of these cell types in acute infection is therefore
not known [22]. These apparently contradictory reports
may be explained by the use of different strains, suggesting
that acute and persistent strains of MNV may have predom-
inantly different tropisms [27]. It will be interesting to
determine whether this is also the case for HuNoV. Our
findings suggest that restricting replication in both cells
types results in lower viral secretion of a persistent MNV
strain. Therefore, further studies are required to determine
whether newly synthesized virus in cells of the lamina prop-
ria could be secreted directly back into the intestinal lumen
through the epithelium, or whether replication in immune
cells indirectly affects secretion by providing more virus to
infect IECs.
Fig. 5. Carrying a target sequence for haematopoietic miR-142–3p and intestinal epithelial miR-215 reduces MNV replication in the
initial phase of a persistent infection in vivo. Mice were infected with 100 ul of each virus recovery supernatant containing equivalent
genome copies and secreted viral genome copies were measured on the indicated days by RT-qPCR. Significance was tested using
two-way Anova with Dunnett’s multiple comparison test to compare each group to the WT control group. ****, P<0.001. n=6.
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Our approach could be used to further investigate whether
norovirus tropism is the same during acute infections and
address the reported discrepancies. Using this approach in a
model where the host develops a symptomatic infection
would also allow assessment of the contribution of replica-
tion in each cell type to pathogenesis and disease, although
symptomatic infection models involve the use of innate or
adaptive immunocompromised mice, which may remove
natural barriers to replication [50, 51]. It would be interest-
ing to determine how replication in each cell type affects
viral dissemination through the intestines and into extra-
intestinal tissues in these models, such as the spleen and
MLN. In our MNV-3 model of persistent infection, replica-
tion in these tissues peaked between days 3 and 5 p.i. [21],
by which time viral replication had overcome restriction by
each miRNA.
Although this approach of exploiting miRNAs has been
successfully applied to selectively control viral tropism and
attenuate a number of other RNA viruses [28, 33, 35], we
encountered several limitations in using it as a tool to to
study MNV tropism. The first was that, given that MNV
only replicates in immune cells in vitro, which all express
miR-142–3p and are resistant to transfection and genetic
manipulation, there was no alternative permissive cell type
to titre the miR-142–3p-restricted viruses and demonstrate
replication in the absence of miR-142–3p. However, we
confirmed that equal levels of encapsidated viral genomes,
and therefore infectious virions, were produced for the
3¢142T virus, and equivalent genome copy numbers were
shed compared to the inoculation dose on day 1 post-
infection in vivo. Conversely, as cultured IEC lines do not
support MNV replication in vitro [10, 27], we did not have
a permissive cell line with endogenous miR-215 expression
to enable in vitro characterization of the miR-215
restriction.
A second major challenge was the difficulty in making large
insertions in the compact MNV genome, which has short
UTRs, without disrupting essential genomic elements or
protein domains that would compromise viral replication.
We were guided here by our previous studies identifying
positions across the genome that tolerated 15 nt insertions
[43, 44]. However, whether the same site tolerates larger
insertions is size- and sequence-specific, and we have found
that many sites that tolerate small epitope tags or random
15 nt insertions do not tolerate insertions of larger sizes,
such as genes for fluorescent proteins of various sizes
(unpublished data). We encountered the same challenge
here with the insertion of MREs into a previously identified
site in the 3¢UTR [43]. Insertions of various single MREs
(23 nt) were tolerated at this position, without replication
being compromised by the insertion itself, as evidenced by
the WT-like replication of the scrambled control viruses,
and differential replication of the miRNA-targeted viruses
correlating with differences in expression of the cognate
miRNA. However, inserting a double miR-142–3p MRE
with a spacer region (51 nt) into the same site reduced the
production of infectious virions, measured as encapsidated
viral genomes. The norovirus 3¢UTR is known to contain
structures that are important for viral replication [52]. This
finding suggests that the 3¢UTR may also impact on genome
encapsidation and viral production, although further studies
are required to confirm this. In the majority of other studies
using this approach, restriction has been achieved in vivo by
inserting at least a double MRE, and in some cases by the
insertion of a cassette containing up to six MREs [28, 31–
33, 53]. A larger number of MREs likely facilitates complete
restriction early in infection and in the face of high levels of
RNA virus genome replication during infection. It has been
suggested that a minimum miRNA copy number threshold
must be exceeded for gene silencing to occur [54]. There-
fore, if the restriction is not complete then it is likely that
the number of newly synthesized genomes could soon out-
number the copy number of the miRNA in each cell and
thereby overcome restriction. As such, replication of MNV-
3 carrying single MREs overcame each miRNA restriction
in the early stages of infection in vivo. The lack of resistance
mutations in the MRE sequences at the point at which
restriction was overcome (5 days p.i.) suggests that a single
MRE did not exert sufficient selection pressure on each
virus, which is also in line with high levels of secreted virus
production from relatively few infected cells in vivo, at least
for IECs [27]. To exert more selective pressure, some studies
have inserted MREs at multiple sites in the genome [32],
which could be a possibility for taking this approach further
for MNV, however, given its short UTRs, the additional
insertions would need to be in coding regions, which can be
complicated by effects at the protein level.
As both the miR-142–3p- and miR-215-targeted viruses
overcame restriction during the acute phase of infection
[21], we could not examine the importance of each cellular
tropism for maintaining persistent infection and shedding.
This may also reflect the fact that several cell types are per-
missive in vivo, so restriction in one cell type may only have
a minor impact. This approach has so far only been applied
to the study of tropism in acute viral infections, and it also
suggests that maintaining restriction in the face of high rates
of mutagenic RNA virus replication may not applicable to
persistent viruses.
Finally, the finding that MNV replicates in IECs in vivo
raises a number of interesting questions and possibilities.
Firstly, a proteinaceous receptor for MNV has recently been
identified, namely CD300lf [55], an Ig domain-containing
molecule expressed on myeloid cells with low expression on
epithelial cells [22]. This suggests that MNV may use a dif-
ferent proteinaceous receptor to enter IECs. As in vitro
replication in cell culture of MNV and HuNoVs is predomi-
nantly at the level of entry [55, 56], identification of this
receptor could by comparison shed light on the long-
sought-after receptor for HuNoV and facilitate the develop-
ment of further in vitro propagation systems for both
viruses.
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METHODS
Cells
The murine macrophage cell line RAW264.7 was main-
tained in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco) containing 10% foetal calf serum (FCS), penicillin
(P) (100 SI units ml 1) and streptomycin (S) (100 µgml 1)
and 10mM HEPES (pH 7.6) at 37

C with 10% CO2. The
murine microglial BV-2 cell line [45] was provided by
Jennifer Pocock (University College London). BV-2 cells
were maintained in DMEM supplemented with 10% FCS
(Biosera), 2mM L-glutamine, 0.075% sodium bicarbonate
(Gibco) and the antibiotics penicillin and streptomycin as
above. BHK cells engineered to express T7 RNA polymerase
(BSR-T7 cells, obtained from Karl-Klaus Conzelmann, Lud-
wid Maximillians University, Munich, Germany) were
maintained in DMEM containing 10% FCS, penicillin (100
SI units ml 1) and streptomycin (100 µgml 1), and 0.5mg
ml 1 G418. For the preparation of bone marrow-derived
macrophage (BMDM), bone marrow cells were harvested
from female C57BL/6 mice and cultured in DMEM contain-
ing 10% FCS, penicillin (100 SI units ml 1) and streptomy-
cin (100 µgml 1). For BMDM differentiation, supernatant
collected from CMG14 cells, which contains macrophage
colony-stimulating factor (M-CSF), was added to the media
for 5–7 days.
Viral reverse genetics
The cDNA clone pT7:MNV 3¢ RZ, containing the WT
MNV-1 genome under the control of a truncated T7 poly-
merase promoter was constructed previously [20]. The
cDNA clone pT7:MNV3 3¢RZ (MNV3-WT) contains the
MNV-3 sequence under the control of the T7 promoter, as
described in [21]. The insertion of MREs into each genome
was achieved by overlap mutagenic PCR (primer details
available upon request). Virus was rescued from cDNA
clones using the reverse-genetics system based on recombi-
nant Fowlpox expressing T7 RNA polymerase, as previously
described [20]. Briefly, 1 µg of each cDNA clone was trans-
fected, using Lipofectamine 2000 transfection reagent (Invi-
trogen), into BSR-T7 cells previously infected with
recombinant Fowlpox virus expressing T7 RNA polymerase
at an m.o.i. of approximately 0.5 p.f.u. per cell. After 48 h
post-transfection, the cells were freeze-thawed at  80

C to
release virus particles.
Viral TCID50 and growth analysis
Fifty per cent tissue culture infectious dose (TCID50) titra-
tions were performed on BV-2 or RAW264.7 cells using 10-
fold serial dilutions, typically over a range of neat to 10–7.
The viral TCID50 ml
–1 was determined by scoring for signs
of cytopathic effect (CPE) at 5 days post-infection by visual
inspection. Multistep growth curve analysis of miRNA-tar-
geted viruses was performed by infecting RAW264.7 cells
with sequence-verified virus at an m.o.i. of 0.01 TCID50/cell.
BMDM cells were infected at an m.o.i. of 10 TCID50/cell, as
titred on RAW 264.7 cells. Virus was harvested at various
time points post-infection through a single freeze-thaw
cycle and virus titre was determined by TCID50 on
RAW264.7 cells.
miRNA extraction and expression analysis
To analyse miRNA expression, RAW264.7 and BV-2 cells
were infected with MNV-1 WT at an m.o.i. of 0.1 TCID50/
cell or were mock-infected, while BMDM cells were infected
at an m.o.i. of 10 TCID50/cell, and the small cellular RNA
fraction was harvested at 20 h p.i. A DNA-based recovery of
MNV-1 was performed in BSR-T7 cells and small RNA spe-
cies were extracted at 24 h post-transfection. In each case
the small cellular RNA fraction (<200 bp) was harvested
using the miRVana RNA isolation kit, as per the manufac-
turer’s instructions. This retains RNA molecules as small as
10 nt. For cDNA synthesis, the TaqMan miRNA reverse-
transcription kit was used (Life Technologies), according to
the manufacturer’s instructions. A thousand nanograms of
RNA extracted from infected and uninfected RAW264.7
cells and BV-2 cells were used with Megaplex RT primers,
Rodent Pool A (Life Technologies). The pool contains pri-
mers specific to 335 and 238 mature unique mouse and rat
miRNAs, respectively, alongside primers for four specific
endogenous controls. The cDNA was then used for qPCR
using TaqMan Rodent miRNA Array A cards (TDLA, Life
Technologies). The TaqMan Rodent miRNA Array A is a
preconfigured 384 well card that can amplify and detect 381
mature rodent miRNAs and 3 control small RNAs (that are
common to those in the Megaplex primer pools). As recom-
mended in the manufacturer’s instructions, 6 µl of cDNA
was mixed with TaqMan Universal PCR 2 Master Mix
(no UNG) (Life Technologies) into a final volume of 900 µl.
Then 100 µl of each mix was loaded into a port on the
TLDA card, which covered two rows of the 384-well card.
The TLDA cards were run on the 7900HT T Fast Real-Time
PCR System and the data were visualized and analysed for
the Ct value of each miRNA using RQ manager software
(Life Technologies). Further analysis was performed using
Microsoft Excel. The Ct value for each miRNA was normal-
ized against the Ct value for the endogenous control small
non-coding nuclear RNA U6, which did not appear to be
altered with infection. RT-qPCR validation was performed
using RT and PCR primer probes specific to a selection of
miRNAs. The RT-qPCR was performed using the same
enzymes and master mixes, but with individual primers for
miR-467a, miR-467c, miR-126, miR-125–5p, miR-124,
miR-10a and the control RNA U6.
Quantification of viral RNA by RT-qPCR
Quantification of viral genome copies from infected cells or
faecal samples was performed by two-step RT-qPCR. Nucle-
ase-resistant encapsidated genomes were produced as previ-
ously described [20], prior to RNA extraction using 100 µl
of treated recovery supernatants. Twenty nanograms of of
RNA from infected cell samples was used for reverse tran-
scription. The amount of RNA used from faecal samples
corresponded to that extracted from 0.5mg of stool. Viral
RNA of known copy number was generated by in vitro tran-
scription of the MNV-1 or MNV-3 cDNA clones and was
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serially diluted to generate a standard curve. Reverse tran-
scription was performed with M-MLV using random hex-
amers, as per the manufacturer’s instructions. qPCR was
performed on the cDNA using a TaqMan Low Rox qPCR
Master Mix (Primer design), with an initial denaturation
step of 8min at 95

C, followed by 50 cycles of 95

C for 10 s
and 60

C for 1min. The genome copy number was interpo-
lated from the standard curve and was calculated per ng of
RNA or per mg of stool, depending on the sample, using
Microsoft Excel. All graphs were produced using GraphPad
Prism version 5 software.
In vivo infections
Three-to-four week old female C57BL/6 mice were inocu-
lated by oral gavage with 100 µl of recovery supernatant of
MNV-3 3¢142T, 3¢215T, 3¢S and WT viruses, which con-
tained equivalent encapsidated viral genome copy numbers.
Each group contained six mice and a control group was
mock-infected. Mice were weighed and faecal samples were
collected on days 0–7, 14, 21 and 28 post-infection, while
mice were euthanized on day 28. Faecal pellets were homog-
enized in PBS (100mgml 1), followed by centrifugation at
4000 r.p.m. for 5min, 4

C. RNA was extracted from 100 µl
of supernatant using the GenElute mammalian total RNA
kit and viral genome copy numbers were determined as
described.
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